Synopsis of some recent tactical application of bioisosteres in drug design.

The concept of isosterism between relatively simple chemical entities was originally contemplated by James Moir in 1909, a notion further refined by H. G. Grimm’s hydride displacement law and captured more effectively in the ideas advanced by Irving Langmuir based on experimental observations. Langmuir coined the term “isostere” and, 18 years in advance of its actual isolation and characterization, predicted that the physical properties of the then unknown ketene would resemble those of diazomethane. The emergence of bioisosteres as structurally distinct compounds recognized similarly by biological systems has its origins in a series of studies published byHans Erlenmeyer in the 1930s, who extended earlier work conducted by Karl Landsteiner. Erlenmeyer showed that antibodies were unable to discriminate between phenyl and thienyl rings or O, NH, and CH2 in the context of artificial antigens derived by reacting diazonium ions with proteins, a process that derivatized the ortho position of tyrosine, as summarized in Figure 1 The term “bioisostere” was introduced by Harris Friedman in 1950 who defined it as compounds eliciting a similar biological effect while recognizing that compounds may be isosteric but not necessarily bioisosteric. This notion anticipates that the application of bioisosterism will depend on context, relying much less on physicochemical properties as the underlying principle for biochemical mimicry. Bioisosteres are typically less than exact structural mimetics and are often more alike in biological rather than physical properties. Thus, an effective bioisostere for one biochemical application may not translate to another setting, necessitating the careful selection and tailoring of an isostere for a specific circumstance. Consequently, the design of bioisosteres frequently introduces structural changes that can be beneficial or deleterious depending on the context, with size, shape, electronic distribution, polarizability, dipole, polarity, lipophilicity, and pKa potentially playing key contributing roles in molecular recognition and mimicry. In the contemporary practice of medicinal chemistry, the development and application of bioisosteres have been adopted as a fundamental tactical approach useful to address a number of aspects associated with the design and development of drug candidates. The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering physical properties, reducing or redirecting metabolism, eliminating or modifying toxicophores, and acquiring novel intellectual property. In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compound optimization and the long-term success of drug candidates. Interesting concepts that may have been poorly effective in the context examined are captured, since the ideas may have merit in alternative circumstances. A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections. Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chemistry setting has been adopted by this community.

[1]  I. Langmuir ISOMORPHISM, ISOSTERISM AND COVALENCE. , 1919 .

[2]  Beziehungen zwischen der Struktur der Antigene und der Spezifität der Antikörper , 1933 .

[3]  E. McDermott,et al.  Action of Nitrogen Trichloride on Proteins: a Synthesis of the Toxic Factor from Methionine , 1950, Nature.

[4]  F. Westheimer The Magnitude of the Primary Kinetic Isotope Effect for Compounds of Hydrogen and Deuterium. , 1961 .

[5]  F. Johnson Allylic strain in six-membered rings , 1968 .

[6]  Pyridine isosteres of the -adrenergic antagonists, 2-(p-nitrophenyl)-1-isopropylamino-2-ethanol and 3-(p-nitrophenoxy)-1-isopropylamino-2-propanol. , 1972, Journal of medicinal chemistry.

[7]  Leo Radom,et al.  Molecular orbital theory of the electronic structure of organic compounds. XII. Conformations, stabilities, and charge distributions in monosubstituted benzenes , 1972 .

[8]  S H Unger,et al.  "Aromatic" substituent constants for structure-activity correlations. , 1973, Journal of medicinal chemistry.

[9]  J. Katz,et al.  Studies with deuterated drugs. , 1975, Journal of pharmaceutical sciences.

[10]  R. Bryan,et al.  Crystal structures of α-trans- and p-methoxy-cinnamic acids and their relation to thermal mesomorphism , 1975 .

[11]  J. C. Emmett,et al.  Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine. , 1977, Journal of medicinal chemistry.

[12]  C. Thornber,et al.  Isosterism and molecular modification in drug design , 1979 .

[13]  Peter A. Kollman,et al.  Methoxy group nonplanarity in o-dimethoxybenzenes. Simple predictive models for conformations and rotational barriers in alkoxyaromatics , 1979 .

[14]  G. Blackburn,et al.  A novel synthesis of α- and γ- fluoroalkylphosphonates , 1981 .

[15]  G. Blackburn,et al.  Monofluoro- and difluoro-methylenebisphosphonic acids: isopolar analogues of pyrophosphoric acid , 1981 .

[16]  B. T. Phillips,et al.  Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists. , 1982, Journal of medicinal chemistry.

[17]  G. M. Luke,et al.  1,2,5-thiadiazole 1-oxide and 1,1-dioxide derivatives. A new class of potent histamine H2-receptor antagonists. , 1982, Journal of medicinal chemistry.

[18]  S. Kurozumi,et al.  Synthesis of chemically stable prostacyclin analogs , 1983 .

[19]  H. Berman,et al.  Structural studies of a new antitumor agent: tiazofurin and its inactive analogues , 1983 .

[20]  B. Testa,et al.  The lipophilicity of deuterium atoms. A comparison of shake-flask and HPLC methods , 1984 .

[21]  H. Vorbrüggen,et al.  Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity. , 1986, Journal of medicinal chemistry.

[22]  J. Domagala,et al.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.

[23]  R. Taft,et al.  Electrostatic proximity effects in the relative basicities and acidities of pyrazole, imidazole, pyridazine, and pyrimidine , 1986 .

[24]  Christopher A. Lipinski,et al.  Chapter 27. Bioisosterism in Drug Design , 1986 .

[25]  R. M. Otoski,et al.  An approach to lipophilic nucleotide phosphate analogs: Synthesis of a lipophilic isostere of ATP , 1988 .

[26]  A. Roszak,et al.  Conformational Flexibility of the Acetoxyphenyl Group Studied by Statistical Analysis of Crystal Structure Data , 1988 .

[27]  C. Swain,et al.  Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines. , 1989, Journal of medicinal chemistry.

[28]  Michael H. Abraham,et al.  Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design , 1989 .

[29]  Robin Taylor,et al.  Use of crystallographic data in searching for isosteric replacements: Composite crystal-field environments of nitro and carbonyl groups† , 1990 .

[30]  L L Iversen,et al.  Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. , 1990, Journal of medicinal chemistry.

[31]  S. Moreland,et al.  Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. , 1990, Journal of medicinal chemistry.

[32]  A Hedberg,et al.  Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents. , 1991, Journal of medicinal chemistry.

[33]  N. Castagnoli,et al.  Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. , 1991, Chemical research in toxicology.

[34]  J. Boyd,et al.  Hydrogen bonding in steroidogenesis: studies on new heterocyclic analogs of estrone that inhibit human estradiol 17 beta-dehydrogenase. , 1991, Biochemical and biophysical research communications.

[35]  S. Moreland,et al.  Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents. , 1992, Journal of medicinal chemistry.

[36]  T. Burke,et al.  A general method for the preparation of benzylic α,α-difluorophosphonic acids; non-hydrolyzable mimemtics of phosphotyrosine , 1992 .

[37]  Edgar F. Meyer,et al.  Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole , 1992 .

[38]  W. Kinney,et al.  Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. , 1992, Journal of medicinal chemistry.

[39]  N. Meanwell,et al.  Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. , 1992, Journal of medicinal chemistry.

[40]  T. Colatsky,et al.  3-hydroxy-3-cyclobutene-1,2-dione: Application of novel carboxylic acid bioisostere to an in-vivo active non-tetrazole angiotensin-II antagonist , 1993 .

[41]  S M Firestine,et al.  A tight binding inhibitor of 5-aminoimidazole ribonucleotide carboxylase. , 1993, Journal of medicinal chemistry.

[42]  A. Abbotto,et al.  Charge mapping in carbanions. Weak charge demand of the cyano group as assessed from a carbon-13 NMR study of carbanions of .alpha.-activated acetonitriles and phenylacetonitriles: breakdown of a myth , 1993 .

[43]  Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring. , 1993, Journal of medicinal chemistry.

[44]  J. Gibbs,et al.  Isolation and structure of chaetomellic acids A and B from Chaetomella acutiseta: farnesyl pyrophosphate mimic inhibitors of ras farnesyl-protein transferase , 1993 .

[45]  N. Meanwell,et al.  Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid. , 1993, Journal of medicinal chemistry.

[46]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[47]  W. Greenlee,et al.  Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements , 1994 .

[48]  R. Chang,et al.  A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist. , 1994, Journal of medicinal chemistry.

[49]  D. Langs,et al.  C-glycosyl bond conformation in oxazofurin: crystallographic and computational studies of the oxazole analogue of tiazofurin. , 1994, Journal of medicinal chemistry.

[50]  R. J. Abraham,et al.  Conformational analysis. Part 22. An NMR and theoretical investigation of the gauche effect in fluoroethanols , 1994 .

[51]  S. Swaminathan,et al.  Deoxyoligonucleotides containing 2′,5′ acetal linkages: Synthesis and hybridization properties , 1994 .

[52]  Inhibitors of sterol synthesis: 3 beta-hydroxy-25,26,26,26,27,27,27- heptafluoro-5 alpha-cholestan-15-one, an analog of a potent hypocholesterolemic agent in which its major metabolism is blocked. , 1994, Biochemical and biophysical research communications.

[53]  N. Kitteringham,et al.  Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. , 1994, Drug metabolism reviews.

[54]  H L Carrell,et al.  Crystallographic studies of two alcohol dehydrogenase-bound analogues of thiazole-4-carboxamide adenine dinucleotide (TAD), the active anabolite of the antitumor agent tiazofurin. , 1994, Biochemistry.

[55]  N. Meanwell,et al.  Non-prostanoid prostacyclin mimetics , 1994 .

[56]  T. J. Nitz,et al.  Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. , 1995, Journal of medicinal chemistry.

[57]  C. Carrell,et al.  Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase. , 1995, Journal of medicinal chemistry.

[58]  K C Nicolaou,et al.  Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol. , 1995, Chemistry & biology.

[59]  J. Williams,et al.  Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles. , 1995, Journal of medicinal chemistry.

[60]  J. Erickson,et al.  Hydrogen Bond Donor Properties of the Difluoromethyl Group , 1995 .

[61]  P. Edwards,et al.  Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. , 1995, Journal of medicinal chemistry.

[62]  M. Matteucci,et al.  Synthesis and hybridization properties of an oligonucleotide analog containing a glucose-derived conformation-restricted ribose moiety and 2′, 5′ formacetal linkages , 1996 .

[63]  M. Raimondo,et al.  (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist. , 1996, Journal of medicinal chemistry.

[64]  I. Gilbert,et al.  Isosteres of nucleoside triphosphates , 1996 .

[65]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design. , 1996, Chemical reviews.

[66]  K. Gibson,et al.  N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region. , 1996, Journal of medicinal chemistry.

[67]  Chong-Hwan Chang,et al.  Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. , 1996, Journal of medicinal chemistry.

[68]  A. Abbotto,et al.  Diheteroarylmethanes. 5.(1) E-Z Isomerism of Carbanions Substituted by 1,3-Azoles: (13)C and (15)N pi-Charge/Shift Relationships as Source for Mapping Charge and Ranking the Electron-Withdrawing Power of Heterocycles. , 1996, The Journal of organic chemistry.

[69]  I. Gilbert,et al.  Lipophilic bioisosteres of nucleoside triphosphates , 1996 .

[70]  Gerhard Klebe,et al.  Oxygen and Nitrogen in Competitive Situations: Which is the Hydrogen‐Bond Acceptor? , 1996 .

[71]  K. Lin,et al.  The synthesis and hybridization properties of an oligonucleotide containing hexafluoroacetone ketal internucleotide linkages , 1996 .

[72]  David W. Christianson,et al.  Novel Binding Mode of Hydroxamate Inhibitors to Human Carbonic Anhydrase II , 1997 .

[73]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[74]  K. Kimata,et al.  Direct chromatographic separation of racemates on the basis of isotopic chirality. , 1997, Analytical chemistry.

[75]  Some influences of fluorine in bioorganic chemistry , 1997 .

[76]  D M Leonard,et al.  Ras farnesyltransferase: a new therapeutic target. , 1997, Journal of medicinal chemistry.

[77]  Robin Taylor,et al.  Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles , 1997 .

[78]  I. Gilbert,et al.  The design and synthesis of nucleoside triphosphate isosteres as potential inhibitors of HIV reverse transcriptase , 1997 .

[79]  Y. Nagao,et al.  Intramolecular Nonbonded S···O Interaction Recognized in (Acylimino)thiadiazoline Derivatives as Angiotensin II Receptor Antagonists and Related Compounds , 1998 .

[80]  J. Pin,et al.  Synthesis and preliminary evaluation of (S)-2-(4'-carboxycubyl)glycine, a new selective mGluR1 antagonist. , 1998, Bioorganic & medicinal chemistry letters.

[81]  M. Berthelot,et al.  Hydrogen-bond basicity pKHB scale of aldehydes and ketones , 1998 .

[82]  P K Jadhav,et al.  De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule. , 1998, Pharmaceutical biotechnology.

[83]  S. Brady,et al.  Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.

[84]  M. Berthelot,et al.  HYDROGEN-BOND BASICITY PKHB SCALE OF SIX-MEMBERED AROMATIC N-HETEROCYCLES , 1998 .

[85]  M. Whitlow,et al.  Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. , 1998, Journal of medicinal chemistry.

[86]  W. T. Borden Effects of electron donation into C–F σ* orbitals: explanations, predictions and experimental tests , 1998 .

[87]  G. Basarab,et al.  Structure-based design of potent inhibitors of scytalone dehydratase: displacement of a water molecule from the active site. , 1998, Biochemistry.

[88]  Combinatorial Chemistry Editorial Policy , 1998 .

[89]  J. Duncia,et al.  The discovery and development of angiotensin II antagonists. , 1998, Pharmaceutical biotechnology.

[90]  M. Berthelot,et al.  THE HYDROGEN-BOND BASICITY PKHB SCALE OF PEROXIDES AND ETHERS , 1998 .

[91]  I. Gilbert,et al.  Design and synthesis of bio-isosteres of thymidine triphosphate. , 1998, Bioorganic & medicinal chemistry letters.

[92]  H. Okuda,et al.  A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[93]  Nguyen-Huu Xuong,et al.  Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase. , 1999 .

[94]  R. Silverman,et al.  2,6-Difluorophenol as a bioisostere of a carboxylic acid: bioisosteric analogues of gamma-aminobutyric acid. , 1999, Journal of medicinal chemistry.

[95]  D. Wade Deuterium isotope effects on noncovalent interactions between molecules. , 1999, Chemico-biological interactions.

[96]  Diheteroarylmethanes. 8.(1) Mapping Charge and Electron-Withdrawing Power of the 1,2,4-Triazol-5-yl Substituent. , 1999, The Journal of organic chemistry.

[97]  A. Jackman,et al.  Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. , 1999, Journal of medicinal chemistry.

[98]  R. Chang,et al.  Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series. , 1999, Journal of medicinal chemistry.

[99]  A. Beatty,et al.  Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. , 1999, Journal of medicinal chemistry.

[100]  R. Chang,et al.  Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones. , 1999, Journal of medicinal chemistry.

[101]  Gautam R. Desiraju,et al.  The Weak Hydrogen Bond: In Structural Chemistry and Biology , 1999 .

[102]  D. Tozer The conformation and internal rotational barrier of benzyl fluoride , 1999 .

[103]  Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side Chains , 1999 .

[104]  M. Bock,et al.  Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety1,2 , 1999 .

[105]  Christian Laurence,et al.  Observations on the strength of hydrogen bonding , 2000 .

[106]  M. Murray,et al.  Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. , 2000, Current drug metabolism.

[107]  J. Azuma,et al.  The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population , 2000, European Journal of Clinical Pharmacology.

[108]  Sung-Hou Kim,et al.  Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. , 2000, Biochemistry.

[109]  M. Reggelin,et al.  Sulfoximines: Structures, Properties and Synthetic Applications , 2000 .

[110]  A. Gilbert,et al.  Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. , 2000, Journal of medicinal chemistry.

[111]  J. Howard,et al.  The preferred conformation of N-β-fluoroethylamides. Observation of the fluorine amide gauche effect , 2000 .

[112]  D. Boschelli,et al.  4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. , 2000, Journal of medicinal chemistry.

[113]  G T Miwa,et al.  The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. , 2000, Toxicology and applied pharmacology.

[114]  L. W. Spruce,et al.  Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. , 2000, Journal of medicinal chemistry.

[115]  D. Denis,et al.  Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. , 2001, Bioorganic & medicinal chemistry.

[116]  M. Witmer,et al.  2-Aryl-2,2-difluoroacetamide FKBP12 ligands: synthesis and X-ray structural studies. , 2001, Organic letters.

[117]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[118]  S. Sieburth,et al.  Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. , 2001, Chemistry & biology.

[119]  L. W. Spruce,et al.  Development of orally active nonpeptidic inhibitors of human neutrophil elastase. , 2001, Journal of medicinal chemistry.

[120]  G. Satzinger Drug discovery and commercial exploitation. , 2001, Drug news & perspectives.

[121]  L. Prézeau,et al.  Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. , 2001, Bioorganic & medicinal chemistry.

[122]  R. Ulrich,et al.  Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. , 2001, Chemico-biological interactions.

[123]  K. Battaile,et al.  Burning fat: the structural basis of fatty acid β-oxidation , 2002 .

[124]  J. Dogné,et al.  Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. , 2002, Journal of medicinal chemistry.

[125]  M. Sekine,et al.  Squaryl group as a new mimic of phosphate group in modified oligodeoxynucleotides: synthesis and properties of new oligodeoxynucleotide analogues containing an internucleotidic squaryldiamide linkage. , 2002, Journal of the American Chemical Society.

[126]  David Critchley,et al.  Squaric acid derivatives as VLA-4 integrin antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[127]  L. Hedstrom Serine protease mechanism and specificity. , 2002, Chemical reviews.

[128]  M. Berthelot,et al.  Site of protonation of nicotine and nornicotine in the gas phase: pyridine or pyrrolidine nitrogen? , 2002, Journal of the American Chemical Society.

[129]  Jaeseung Kim,et al.  Silanediol-based inhibitor of thermolysin. , 2002, Bioorganic & medicinal chemistry letters.

[130]  G. Prestwich,et al.  Concise synthesis of acyl migration-blocked 1,1-difluorinated analogues of lysophosphatidic acid. , 2002, The Journal of organic chemistry.

[131]  L. Benet,et al.  Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. , 2002, Chemical research in toxicology.

[132]  K. Koehler,et al.  A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. , 2002, Bioorganic & medicinal chemistry letters.

[133]  Robert P. Sheridan,et al.  The Most Common Chemical Replacements in Drug-Like Compounds , 2002, J. Chem. Inf. Comput. Sci..

[134]  G. Bemis,et al.  Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding , 2002, Proteins.

[135]  N. Curtin,et al.  Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. , 2002, Journal of medicinal chemistry.

[136]  Shuji Tomoda,et al.  Statistical and theoretical investigations on the directionality of nonbonded S...O interactions. Implications for molecular design and protein engineering. , 2002, Journal of the American Chemical Society.

[137]  M. R. Barbachyn,et al.  Oxazolidinone structure-activity relationships leading to linezolid. , 2003, Angewandte Chemie.

[138]  C. Perrin,et al.  Beta-deuterium isotope effects on amine basicity, "inductive" and stereochemical. , 2003, Journal of the American Chemical Society.

[139]  R. Kurumbail,et al.  Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex. , 2003, Bioorganic & medicinal chemistry letters.

[140]  W. Trager,et al.  The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[141]  R. Kurumbail,et al.  Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors. , 2003, Journal of medicinal chemistry.

[142]  Zheng Yang,et al.  Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. , 2003, Journal of medicinal chemistry.

[143]  B. Tomczuk,et al.  Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[144]  M. Berthelot,et al.  The nicotinic pharmacophore: thermodynamics of the hydrogen-bonding complexation of nicotine, nornicotine, and models. , 2003, The Journal of organic chemistry.

[145]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[146]  G. Colombo,et al.  Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. , 2003, Chemistry.

[147]  Hung‐wen Liu,et al.  Reversal of the apparent regiospecificity of NAD(P)H-dependent hydride transfer: the properties of the difluoromethylene group, a carbonyl mimic. , 2003, Journal of the American Chemical Society.

[148]  W. Bains,et al.  Silicon chemistry as a novel source of chemical diversity in drug design. , 2003, Current opinion in drug discovery & development.

[149]  Graham A Showell,et al.  Chemistry challenges in lead optimization: silicon isosteres in drug discovery. , 2003, Drug discovery today.

[150]  W. Hagmann,et al.  Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. , 2003, Journal of mass spectrometry : JMS.

[151]  Jaroslaw Meller,et al.  Deuterium isotope effects on hydrophobic interactions: the importance of dispersion interactions in the hydrophobic phase. , 2003, Journal of the American Chemical Society.

[152]  P. Lam,et al.  Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. , 2003, Journal of medicinal chemistry.

[153]  C. R. Briggs,et al.  The CF bond as a tool in the conformational control of amides , 2003 .

[154]  F. Leroux Atropisomerism, Biphenyls, and Fluorine: A Comparison of Rotational Barriers and Twist Angles , 2004, Chembiochem : a European journal of chemical biology.

[155]  J. Clader The discovery of ezetimibe: a view from outside the receptor. , 2004, Journal of medicinal chemistry.

[156]  Martin Stahl,et al.  Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.

[157]  B. Tomczuk,et al.  Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. , 2004, Bioorganic & medicinal chemistry letters.

[158]  M. Zanda Trifluoromethyl group: an effective xenobiotic function for peptide backbone modification , 2004 .

[159]  S. Sieburth,et al.  Silanediol peptidomimetics. Evaluation of four diastereomeric ACE inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[160]  N. Curtin,et al.  Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. , 2004, Journal of medicinal chemistry.

[161]  J. Lex,et al.  Proline-Derived N-Sulfonylcarboxamides: Readily Available, Highly Enantioselective and Versatile Catalysts for Direct Aldol Reactions , 2004 .

[162]  Rajeev S. Muthyala,et al.  The use of squaric acid as a scaffold for cofacial phenyl rings. , 2004, Organic letters.

[163]  Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa. , 2004, Bioorganic & medicinal chemistry letters.

[164]  M. Bock,et al.  2,3-diaminopyridine bradykinin B1 receptor antagonists. , 2004, Journal of medicinal chemistry.

[165]  C. R. Briggs,et al.  The observation of a large gauche preference when 2-fluoroethylamine and 2-fluoroethanol become protonated. , 2004, Organic & biomolecular chemistry.

[166]  G. Showell,et al.  Exploitation of silicon medicinal chemistry in drug discovery , 2004, Expert opinion on investigational drugs.

[167]  Fluorinated peptidomimetics: synthesis, conformational and biological features , 2004 .

[168]  Ioannis Nicolaou,et al.  [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor. , 2004, Journal of medicinal chemistry.

[169]  Kengo Watanabe,et al.  Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. , 2004, Journal of medicinal chemistry.

[170]  Virginie B. Arnaud,et al.  Multiple Hydrogen-Bond Accepting Capacities of Polybasic Molecules: The Case of Cotinine , 2004 .

[171]  C. Gabel,et al.  Benzimidazolone p38 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[172]  G. Prestwich,et al.  Synthesis of difluoromethyl substituted lysophosphatidic acid analogues , 2004 .

[173]  M. Bock,et al.  Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates. , 2005, Chemical research in toxicology.

[174]  J. Baell,et al.  Phosphate isosteres in medicinal chemistry. , 2005, Current medicinal chemistry.

[175]  Ricardo L. Mancera,et al.  Including Tightly-Bound Water Molecules in de Novo Drug Design. Exemplification through the in Silico Generation of Poly(ADP-ribose)polymerase Ligands , 2005, J. Chem. Inf. Model..

[176]  Jon Read,et al.  Structure-based design of protein tyrosine phosphatase-1B inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[177]  Dennis E Danley,et al.  Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase. , 2005, Journal of medicinal chemistry.

[178]  Gulzar Ahmed,et al.  5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. , 2005, Journal of medicinal chemistry.

[179]  R. Hanzlik,et al.  Cyclopropylamine inactivation of cytochromes P450: role of metabolic intermediate complexes. , 2005, Archives of biochemistry and biophysics.

[180]  A. Slawin,et al.  The vicinal F-C-C-F moiety as a tool for influencing peptide conformation. , 2005, Chemical communications.

[181]  E. ter Haar,et al.  CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor. , 2005, Journal of medicinal chemistry.

[182]  E. Liu,et al.  Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[183]  P. Marathe,et al.  Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization , 2006, Cancer Chemotherapy and Pharmacology.

[184]  Karl Blom,et al.  Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. , 2005, Journal of medicinal chemistry.

[185]  P. Lam,et al.  Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[186]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[187]  T. Rana,et al.  Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine. , 2005, Bioorganic & medicinal chemistry letters.

[188]  Patricia Andrade-Gordon,et al.  In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. , 2005, Journal of medicinal chemistry.

[189]  C. Perrin,et al.  Stereochemistry of β-deuterium isotope effects on amine basicity , 2005 .

[190]  M. Jung,et al.  gem-disubstituent effect: theoretical basis and synthetic applications. , 2005, Chemical reviews.

[191]  William J Greenlee,et al.  Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. , 2005, Journal of medicinal chemistry.

[192]  B. Matthews,et al.  Structural analysis of silanediols as transition-state-analogue inhibitors of the benchmark metalloprotease thermolysin. , 2005, Biochemistry.

[193]  M. Sekine,et al.  Synthesis and Properties of New Nucleotide Analogues Possessing Squaramide Moieties as New Phosphate Isosters , 2005 .

[194]  Virginie B. Arnaud,et al.  Hydrogen-bond accepting strength of protonated nicotine. , 2005, The journal of physical chemistry. A.

[195]  M. Bower,et al.  Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. , 2006, Journal of medicinal chemistry.

[196]  Richard O Jenkins,et al.  Toxicology of fluoroacetate: a review, with possible directions for therapy research , 2006, Journal of applied toxicology : JAT.

[197]  A. Savarino A historical sketch of the discovery and development of HIV-1 integrase inhibitors , 2006, Expert opinion on investigational drugs.

[198]  Rajesh Odedra,et al.  Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. , 2006, Journal of medicinal chemistry.

[199]  L. P. Mašič Arginine mimetic structures in biologically active antagonists and inhibitors. , 2006, Current medicinal chemistry.

[200]  C. Wermuth,et al.  Similarity in drugs: reflections on analogue design. , 2006, Drug discovery today.

[201]  V. Kukhar,et al.  Fluorinated phosphonates: synthesis and biomedical application. , 2006, Chemical reviews.

[202]  J. Montana,et al.  Synthesis, crystal structure analysis, and pharmacological characterization of desmethoxy-sila-venlafaxine, a derivative of the serotonin/noradrenaline reuptake inhibitor sila-venlafaxine , 2006 .

[203]  D. Boger,et al.  Delineation of a fundamental alpha-ketoheterocycle substituent effect for use in the design of enzyme inhibitors. , 2006, Journal of the American Chemical Society.

[204]  J. Montana,et al.  Sila-venlafaxine, a Sila-Analogue of the Serotonin/Noradrenaline Reuptake Inhibitor Venlafaxine: Synthesis, Crystal Structure Analysis, and Pharmacological Characterization , 2006 .

[205]  F. Schneider,et al.  Enhanced Plasma Concentration by Selective Deuteration of Rofecoxib in Rats , 2006, Arzneimittelforschung.

[206]  J. Montana,et al.  (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. , 2006, Bioorganic & medicinal chemistry letters.

[207]  F. Baumberger,et al.  Synthesis of Fluoro Analogues of 3,4‐(Methylenedioxy)amphetamine (MDA) and Its Derivatives , 2006, Chemistry & biodiversity.

[208]  S. Sieburth,et al.  Silanediol Protease Inhibitors: From Conception to Validation , 2006 .

[209]  M. Dwyer,et al.  Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[210]  E. Carreira,et al.  Oxetanes as promising modules in drug discovery. , 2006, Angewandte Chemie.

[211]  M. Dwyer,et al.  Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. , 2006, Journal of medicinal chemistry.

[212]  L. Prade,et al.  Replacement of Isobutyl by Trifluoromethyl in Pepstatin A Selectively Affects Inhibition of Aspartic Proteinases , 2006, Chembiochem : a European journal of chemical biology.

[213]  M. Bock,et al.  Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists. , 2006, Journal of medicinal chemistry.

[214]  Celia A. Schiffer,et al.  Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease , 2007, Journal of Virology.

[215]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[216]  A. Franz The synthesis of biologically active organosilicon small molecules. , 2007, Current opinion in drug discovery & development.

[217]  M. P. Freitas,et al.  Conformational and stereoelectronic investigation in 1,2-difluoropropane : The gauche effect , 2007 .

[218]  John Roderick,et al.  Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). , 2007, Bioorganic & medicinal chemistry letters.

[219]  M. Berthelot,et al.  The exceptional hydrogen-bond properties of neutral and protonated lobeline. , 2007, The journal of physical chemistry. A.

[220]  C. Perrin,et al.  Secondary deuterium isotope effects on the acidity of carboxylic acids and phenols. , 2007, Journal of the American Chemical Society.

[221]  R. Vince,et al.  Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality. , 2007, Bioorganic & medicinal chemistry letters.

[222]  Andrew P Combs Structure-based drug design of new leads for phosphatase research. , 2007, IDrugs : the investigational drugs journal.

[223]  Andrew D Westwell,et al.  The role of fluorine in medicinal chemistry , 2007, Journal of enzyme inhibition and medicinal chemistry.

[224]  Rongshi Li,et al.  Design and Synthesis of Human Immunodeficiency Virus Entry Inhibitors: Sulfonamide as an Isostere for the α-Ketoamide Group , 2007 .

[225]  P. Marlière,et al.  Polymerase-catalyzed synthesis of DNA from phosphoramidate conjugates of deoxynucleotides and amino acids , 2007, Nucleic acids research.

[226]  A. Volonterio,et al.  The Trifluoroethylamine Function as Peptide Bond Replacement , 2007, ChemMedChem.

[227]  P. Herdewijn,et al.  Amino acid phosphoramidate nucleotides as alternative substrates for HIV-1 reverse transcriptase. , 2007, Angewandte Chemie.

[228]  A. Marino,et al.  Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. , 2007, Bioorganic & medicinal chemistry letters.

[229]  D. Catarzi,et al.  Competitive AMPA receptor antagonists , 2007, Medicinal research reviews.

[230]  Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety. , 2007, Bioorganic & medicinal chemistry letters.

[231]  Mark R Player,et al.  2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[232]  Andrew Tebben,et al.  A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. , 2007, Bioorganic & medicinal chemistry letters.

[233]  J. Montana,et al.  Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry. , 2007, Bioorganic & medicinal chemistry letters.

[234]  Respiratory syncytial virus - The discovery and optimization of orally bioavailable fusion inhibitors , 2007 .

[235]  K. Sillar,et al.  Synthesis, Conformation and Biological Evaluation of the Enantiomers of 3‐Fluoro‐γ‐Aminobutyric Acid ((R)‐ and (S)‐3F‐GABA): An Analogue of the Neurotransmitter GABA , 2007, Chembiochem : a European journal of chemical biology.

[236]  Virginie B. Arnaud,et al.  Hydrogen-bond interactions of nicotine and acetylcholine salts: a combined crystallographic, spectroscopic, thermodynamic and theoretical study. , 2007, Chemistry.

[237]  K. Glaser,et al.  Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. , 2007, Journal of medicinal chemistry.

[238]  D. MacMillan,et al.  The advent and development of organocatalysis , 2008, Nature.

[239]  R. Seifert,et al.  Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists. , 2008, Journal of medicinal chemistry.

[240]  Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[241]  Saul H Rosenberg,et al.  Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.

[242]  R. Syed,et al.  3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. , 2008, Journal of medicinal chemistry.

[243]  B. Maryanoff,et al.  Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. , 2008, Bioorganic & medicinal chemistry.

[244]  A. Mutlib,et al.  Application of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studies. , 2008, Chemical research in toxicology.

[245]  S. Grimme,et al.  Conformational preferences and basicities of monofluorinated cyclopropyl amines in comparison to cyclopropylamine and 2-fluoroethylamine. , 2008, Organic & biomolecular chemistry.

[246]  Philippe Marlière,et al.  Enzymatically Catalyzed DNA Synthesis Using L‐Asp‐dGMP, L‐Asp‐dCMP, and L‐Asp‐dTMP , 2008, Chemistry & biodiversity.

[247]  M. Wendt Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction , 2008, Expert opinion on drug discovery.

[248]  A. Flohr,et al.  Substituted 2-oxo-azepane derivatives are potent, orally active γ-secretase inhibitors , 2008 .

[249]  P. Lam,et al.  Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa. , 2008, Bioorganic & medicinal chemistry letters.

[250]  E. Carreira,et al.  Spirocyclic oxetanes: synthesis and properties. , 2008, Angewandte Chemie.

[251]  D. Bonnet-Delpon,et al.  Bioorganic and Medicinal Chemistry of Fluorine , 2008 .

[252]  A. Doweyko,et al.  The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. , 2008, Bioorganic & medicinal chemistry letters.

[253]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[254]  B. Wünsch,et al.  Sila‐Haloperidol, a Silicon Analogue of the Dopamine (D2) Receptor Antagonist Haloperidol: Synthesis, Pharmacological Properties, and Metabolic Fate , 2008, ChemMedChem.

[255]  F. Giacalone,et al.  Supported proline and proline-derivatives as recyclable organocatalysts. , 2008, Chemical Society reviews.

[256]  S. Purser,et al.  Fluorine in medicinal chemistry. , 2008, Chemical Society reviews.

[257]  Martin Stahl,et al.  Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis , 2008, J. Chem. Inf. Model..

[258]  Youwei Yan,et al.  Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. , 2008, Journal of medicinal chemistry.

[259]  C. Perrin,et al.  Nonadditivity of secondary deuterium isotope effects on basicity of trimethylamine. , 2008, Journal of the American Chemical Society.

[260]  V. Rawal,et al.  Chiral squaramide derivatives are excellent hydrogen bond donor catalysts. , 2008, Journal of the American Chemical Society.

[261]  David O'Hagan,et al.  Understanding organofluorine chemistry. An introduction to the C-F bond. , 2008, Chemical Society reviews.

[262]  S. Semus,et al.  Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. , 2008, Journal of medicinal chemistry.

[263]  L. Hunter,et al.  The multi-vicinal fluoroalkane motif: an examination of 2,3,4,5-tetrafluorohexane stereoisomers. , 2008, Organic & biomolecular chemistry.

[264]  B. Johns,et al.  Advances in two-metal chelation inhibitors of HIV integrase , 2008 .

[265]  B. Tomczuk,et al.  Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. , 2008, Bioorganic & medicinal chemistry letters.

[266]  Irene T Weber,et al.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. , 2008, Accounts of chemical research.

[267]  K. Hayashi,et al.  Intramolecular nonbonded S...N interaction in rabeprazole. , 2008, Chemical & pharmaceutical bulletin.

[268]  R. Syed,et al.  Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. , 2008, Journal of medicinal chemistry.

[269]  Y. Sham,et al.  Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. , 2008, Bioorganic & medicinal chemistry letters.

[270]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[271]  E. Garvey,et al.  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. , 2009, Bioorganic & medicinal chemistry letters.

[272]  W. L. Jorgensen,et al.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization. , 2009, Journal of the American Chemical Society.

[273]  M. Chordia,et al.  In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation. , 2009, Chemical research in toxicology.

[274]  Arun K. Ghosh Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. , 2009, Journal of medicinal chemistry.

[275]  Moshfiqur Rahman,et al.  Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2009, Bioorganic & medicinal chemistry letters.

[276]  M. Lamb,et al.  Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[277]  K. Parris,et al.  Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). , 2009, Bioorganic & medicinal chemistry.

[278]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[279]  Raymond C Stevens,et al.  Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. , 2009, Journal of the American Chemical Society.

[280]  N. Meanwell,et al.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity , 2009, Journal of medicinal chemistry.

[281]  N. Garbacki,et al.  Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. , 2009, Journal of medicinal chemistry.

[282]  H. Gronemeyer,et al.  Silicon Analogues of the RXR‐Selective Retinoid Agonist SR11237 (BMS649): Chemistry and Biology , 2009, ChemMedChem.

[283]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[284]  H. Gronemeyer,et al.  Synthesis and Pharmacological Characterization of Disila‐AM80 (Disila‐tamibarotene) and Disila‐AM580, Silicon Analogues of the RARα‐Selective Retinoid Agonists AM80 (Tamibarotene) and AM580 , 2009, ChemMedChem.

[285]  G. Candiani,et al.  Assessing the Bioisosterism of the Trifluoromethyl Group with a Protease Probe , 2009, ChemMedChem.

[286]  Lili Hu,et al.  Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase. , 2009, Journal of medicinal chemistry.

[287]  R. De Francesco,et al.  Mechanism of Hepatitis C Virus RNA Polymerase Inhibition with Dihydroxypyrimidines , 2009, Antimicrobial Agents and Chemotherapy.

[288]  B. Déprez,et al.  Hydroxamates: relationships between structure and plasma stability. , 2009, Journal of medicinal chemistry.

[289]  A. Volonterio,et al.  Psi[CH(CF(3))NH]Gly-peptides: synthesis and conformation analysis. , 2009, Organic & biomolecular chemistry.

[290]  Amanda Yarnell,et al.  HEAVY-HYDROGEN DRUGS TURN HEADS, AGAIN , 2009 .

[291]  A. Slawin,et al.  Synthesis and Vanilloid Receptor (TRPV1) Activity of the Enantiomers of α‐Fluorinated Capsaicin , 2009, ChemBioChem.

[292]  M. Zanda,et al.  Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins , 2009, ChemMedChem.

[293]  P. Herdewijn,et al.  Phosphodiester Substrates for Incorporation of Nucleotides in DNA Using HIV‐1 Reverse Transcriptase , 2009, Chembiochem : a European journal of chemical biology.

[294]  Njoroge Fg,et al.  A review of HCV protease inhibitors. , 2009 .

[295]  Philippe Marlière,et al.  Toward Safe Genetically Modified Organisms through the Chemical Diversification of Nucleic Acids , 2009, Chemistry & biodiversity.

[296]  Christian Laurence,et al.  The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists. , 2009, Journal of medicinal chemistry.

[297]  E. Garvey,et al.  The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. , 2009, Bioorganic & medicinal chemistry letters.

[298]  P. Herdewijn,et al.  Delta-di-carboxybutyl phosphoramidate of 2'-deoxycytidine-5'-monophosphate as substrate for DNA polymerization by HIV-1 reverse transcriptase. , 2009, Bioorganic & medicinal chemistry.

[299]  M. Suresh,et al.  Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2009, Bioorganic & medicinal chemistry letters.

[300]  F. Maltais,et al.  In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. , 2009, Journal of medicinal chemistry.

[301]  Vijay T. Ahuja,et al.  A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. , 2009, Journal of medicinal chemistry.

[302]  A. Brown,et al.  Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. , 2009, Bioorganic & medicinal chemistry letters.

[303]  R. Seifert,et al.  NG‐Acylated Aminothiazolylpropylguanidines as Potent and Selective Histamine H2 Receptor Agonists , 2009, ChemMedChem.

[304]  Xiaohong Liu,et al.  RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. , 2009, Journal of medicinal chemistry.

[305]  D. Bolognesi,et al.  Heterobiaryl human immunodeficiency virus entry inhibitors. , 2009, Journal of medicinal chemistry.

[306]  T. Spicer,et al.  Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. , 2009, Bioorganic & medicinal chemistry letters.

[307]  M. Suresh,et al.  Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2009, Journal of medicinal chemistry.

[308]  K. Sanderson Big interest in heavy drugs , 2009, Nature.

[309]  Virginie B. Arnaud,et al.  Hydrogen-Bond Accepting Strength of Five-Membered N-Heterocycles: The Case of Substituted Phenylpyrrolines and Myosmines , 2009 .

[310]  E. Corey,et al.  Strong conformational preferences of heteroaromatic ethers and electron pair repulsion. , 2010, Organic letters.

[311]  M. Toda,et al.  Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[312]  Vijay T. Ahuja,et al.  Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[313]  P. Marlière,et al.  Iminodiacetic-phosphoramidates as metabolic prototypes for diversifying nucleic acid polymerization in vivo , 2010, Nucleic Acids Research.

[314]  R. F. Reinoso,et al.  Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. , 2010, Bioorganic & medicinal chemistry letters.

[315]  S. Umland,et al.  Discovery and SAR of hydantoin TACE inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[316]  Daniel P. Walker,et al.  Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. , 2010, Chemical research in toxicology.

[317]  T. Mourik,et al.  A DFT study on the origin of the fluorine gauche effect in substituted fluoroethanes , 2010 .

[318]  J. Deadman,et al.  Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold. , 2010, Bioorganic & medicinal chemistry letters.

[319]  Matthew R. Lee,et al.  Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors. , 2010, Journal of medicinal chemistry.

[320]  J. Bauman,et al.  Metabolism-guided design of short-acting calcium-sensing receptor antagonists. , 2010, ACS medicinal chemistry letters.

[321]  X. Fradera,et al.  4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. , 2010, Bioorganic & medicinal chemistry letters.

[322]  Gerhard Klebe,et al.  Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.

[323]  Khaled R. A. Abdellatif,et al.  Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1,2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[324]  Takashi Watanabe Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas , 2010, Expert opinion on investigational drugs.

[325]  A. Brown,et al.  Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent. , 2010, Bioorganic & medicinal chemistry letters.

[326]  D. Cheney,et al.  Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.

[327]  B. Tomczuk,et al.  Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. , 2010, Journal of medicinal chemistry.

[328]  M. Suresh,et al.  Phenylacetic acid regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2010, Bioorganic & medicinal chemistry letters.

[329]  M. Lamb,et al.  Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[330]  M. Suresh,et al.  Synthesis and biological evaluation of N-difluoromethyl-1,2-dihydropyrid-2-one acetic acid regioisomers: dual inhibitors of cyclooxygenases and 5-lipoxygenase. , 2010, Bioorganic & medicinal chemistry letters.

[331]  Terry K. Smith,et al.  Rationally designed squaryldiamides - a novel class of sugar-nucleotide mimics? , 2010, Organic & biomolecular chemistry.

[332]  A. Hamacher,et al.  Sila-Trifluperidol, a Silicon Analogue of the Dopamine (D2) Receptor Antagonist Trifluperidol: Synthesis and Pharmacological Characterization , 2010 .

[333]  E. Carreira,et al.  Oxetanes as versatile elements in drug discovery and synthesis. , 2010, Angewandte Chemie.

[334]  Y. Sham,et al.  Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease. , 2010, Bioorganic & medicinal chemistry.

[335]  A. Combs Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. , 2010, Journal of medicinal chemistry.

[336]  R. Tacke,et al.  In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange , 2010, Drug Metabolism and Disposition.

[337]  D. Lodowski,et al.  Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. , 2010, Journal of medicinal chemistry.

[338]  C. Sawyers,et al.  Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). , 2010, Journal of medicinal chemistry.

[339]  Vijay T. Ahuja,et al.  Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite Formation , 2010, Drug Metabolism and Disposition.

[340]  J. Deadman,et al.  Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[341]  J. Deadman,et al.  Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: azoles: effective metal chelators. , 2010, Bioorganic & medicinal chemistry letters.

[342]  P. Herdewijn,et al.  Influence of the Linkage between Leaving Group and Nucleoside on Substrate Efficiency for Incorporation in DNA Catalyzed by Reverse Transcriptase , 2010, Chembiochem : a European journal of chemical biology.

[343]  A. Doweyko,et al.  Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[344]  Steven V. Fox,et al.  Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists. , 2010, ACS medicinal chemistry letters.

[345]  Franz Schuler,et al.  Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.

[346]  Shobha N. Bhattachar,et al.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.

[347]  P. Marlière,et al.  3-Phosphono-L-alanine as pyrophosphate mimic for DNA synthesis using HIV-1 reverse transcriptase. , 2011, Organic & biomolecular chemistry.